COMP <GO>
HAE vs ABBV // ALTMAN Z-SCORE & DEBT/EQUITY
Haemonetics Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: HAE 2
— ABBV 10
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: ABBV
LAST: $119.79 (+1.24%) • MKT CAP: $5.45B
balance-sheet
3.89
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
balance-sheet
5.33
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HAE VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HAE | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 59.00% | 70.20% | -11.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 8.40% | 29.00% | -20.60 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 32.5x | 33.3x | -0.80 | HAE | /valuation <GO> |
| Free Cash Flow Yield | 4.78% | 3.47% | +1.31 | HAE | /fcf-yield <GO> |
| Operating Margin | 11.70% | 24.60% | -12.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 0.00% | 6.90% | -6.90 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | -2.00% | 8.60% | -10.60 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.89 | 5.33 | -1.44 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.6 | 65.1 | -1.50 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.00 | 1.15 | -0.15 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.45B | $513.86B | -$508.41B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HAE REV | ABBV REV | HAE GROSS % | ABBV GROSS % | HAE FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | $61.16B | 59.0% | 70.2% | $260.4M | $17.82B |
| FY 2024 | $1.36B | $56.33B | 55.0% | 70.0% | $142.4M | $17.83B |
| FY 2023 | $1.31B | $54.32B | — | — | $122.8M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HAE // BETA 1.00
ABBV // BETA 1.15